Quince Therapeutics, Inc. (QNCX) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Quince Therapeutics Inc (QNCX) 3-Minute Overview > **💡 One-Sentence Summary** > > Quince is a tiny US biotech whose main rare‑disease Phase 3 drug just failed, and the company is now effectively in “strategic alternatives / restructuring” mode rather than a straightforward drug development story. > **📍 Basic Profile** > > Market Cap **~$11.1 million** · Biotechnology · NASDAQ · Price **$0.20** --- > **⚡ 3 Things You Should Know** > > 1. ⚠️ **Core drug setback:** The pivotal Phase 3 NEAT trial for its lead A‑T asset (eDSP) failed to hit the primary and key secondary endpoints – for a small biotech, that often wipes out the original investment thesis and makes future funding harder. > > 2. 🔄 **Now a “special situation,” not a classic growth biotech:** Management has hired LifeSci Capital to explore “strategic alternatives” and is restructuring – this usually means options like asset sales, reverse mergers, or even liquidation rather than simply “try another Phase 3.” > > 3. 🎢 **Penny‑stock volatility with weak fundamentals:** Shares trade at $0.20 vs a 52‑week high of ~$4.55, with deeply negative ROE/ROA and persistent losses; any move now is likely driven more by deal speculation and trading flows than by fundamentals. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Negative earnings, ROE ~‑370%, ROA ~‑50%, burning cash (negative cash flow per share) | > | Growth Rate | Slow🐢 | No clear positive revenue/earnings growth trend; recent EPS misses and R&D setback | > | Financial Health | Tight🧡 | Current ratio ~1.1 (barely ab